A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Atezolizumab (Primary) ; Atezolizumab (Primary) ; Hyaluronidase (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Registrational
- Acronyms IMscin001
- Sponsors Roche
Most Recent Events
- 24 Jan 2025 Status changed from active, no longer recruiting to completed.
- 25 Sep 2024 This trial has been completed in Latvia according to European Clinical Trials Database record.
- 13 Sep 2024 According to a Roche media release, company announced that the the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. The FDA approval is based on pivotal data from the Phase IB/III IMscin001 study.